Participate in Research at CU Anschutz

For Patients on Part A: D with a solid tumor, lymphoma or desmoid tumor that has either come back or does not respond to therapy, or a desmoid tumor that cannot be removed safely by surgery. For Patients on Part B: Diagnosed with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor (HCC and hepatoblastoma), Wilms tumor or tumors with changes in a gene family known as the Wnt pathway. The overall goals of this study are: - This is called a Phase 1/2 study because the goal is to find the highest safe dose of tegavivint that can be given without causing severe side effects - To learn what kind of side effects tegavivint may cause - To learn more about the pharmacology (how your body handles the drug) of tegavivint - To determine whether tegavivint is a beneficial treatment for your cancer The study will be testing different doses of the study drug tegavivint to find the safest dose. Up to 4 different doses of tegavivint may be studied.